Navigation Links
QIAGEN and Bayer HealthCare Partner to Develop Companion Diagnostics to Guide Treatment Decisions for Targeted Cancer Therapies
Date:10/25/2012

HILDEN, Germany, October 25, 2012 /PRNewswire/ --

  • QIAGEN and Bayer HealthCare signed collaboration agreement aimed at advancing both companies positions in personalized medicine
  • The programs pair QIAGEN companion diagnostic solutions with innovative targeted therapies for patients with solid tumors developed by Bayer HealthCare
  • Agreement provides framework for further collaboration projects

QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) and Bayer HealthCare today announced a collaboration agreement for the development and commercialization of companion diagnostics paired with novel Bayer HealthCare drugs, initially to enhance the treatment of various solid tumors. Companion diagnostics are tests that unlock molecular information from each patient's tumor genome to guide treatment decisions with medications for cancers or other diseases. The parties will also collaborate on the development of novel technologies for patient profiling which may result in innovative research-use-only products for exploratory and translational medicine. Financial details were not disclosed.

The targeted companion diagnostics will be designed to run on the QIAsymphony family of automated instruments, which is transforming laboratory workflows and helping disseminate standardized, regulator-approved diagnostics.

"We are very pleased to partner with Bayer HealthCare in developing companion diagnostics to improve life for cancer patients. As healthcare providers increasingly select the right drugs based on each individual's genomic information, the treatment of cancer is undergoing a revolution," said Dr. Helge Lubenow, Senior Vice President Molecular Diagnostics Business Area and Member of the Executive Committee of QIAGEN. "The first collaborations for Bayer HealthCare and QIAGEN include companion diagnostics ba
'/>"/>

SOURCE Qiagen N V
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. QIAGEN Acquires AmniSure International to Add Unique Assay to Emerging Point of Need Portfolio
2. QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to Worlds Poorest Countries
3. BioHealth Innovation, Inc. Appoints Qiagens Douglas Liu to Board of Directors
4. QIAGEN Gains Rights to Genomic Biomarkers for Lung, Brain and Other Cancers to Expand its Pipeline of Companion Diagnostics
5. QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection
6. Bayer Advanced(TM) Sets Sights on New Partnerships in 2013
7. Bayer HealthCares Cotavance® Drug Eluting Balloon With Paccocath® Technology Reduced Five-Year Target Lesion Revascularization Rates by 59 Percent in PAD Patients Compared to Those Treated With Uncoated Balloon
8. AspenBio to Present at 2012 Aegis Healthcare Conference
9. Neuralstem President And CEO To Present At The 2012 Rodman & Renshaw Annual Healthcare Conference
10. Lexicon Pharmaceuticals To Present At The Morgan Stanley Global Healthcare Conference
11. AtheroNova to Present at Rodman & Renshaw 14th Annual Healthcare Conference in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 Pipette.com has added ... to their comprehensive portfolio of Eppendorf products. , The ... purchase a Centrifuge 5424/5424 R and receive the following:, ... Eppendorf Research plus or Eppendorf Reference 2 , ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Selexis SA, ... mammalian Research Cell Banks (RCBs) used for drug discovery ... Cell Banks will include Next-Generation Sequencing (NGS) ... architecture de-risks biologic manufacturing by ensuring the integrity of ...
(Date:1/22/2015)... Jan. 22. 2015  Varian Medical Systems (NYSE: VAR ... honored for its commitment to sustainability with inclusion on a ... the highest ranked healthcare equipment company among the Corporate Knights ... World Economic Forum at Davos, Switzerland . ...
(Date:12/24/2014)... 2014  United Therapeutics Corporation (NASDAQ: UTHR ) ... ) has submitted a pre-market approval application to the ... of Medtronic,s SynchroMed ® II implantable drug infusion ... United Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously ...
Breaking Biology Technology:Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Varian Honored Among World's 100 Most Sustainable Corporations 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
... AKRON, Ohio , June 16 On Wednesday, June 23 ... promises to inspire renewed hope for new jobs in Ohio . ... will share their insight on innovation, global commerce and the new skills needed ... www.ohio.com/jobgrowth . , , , ...
... and SAN DIEGO , June 16 ... Biosciences, Inc. (Nasdaq: NBIX ) today announced that ... and commercialize elagolix for the treatment of endometriosis-related pain. ... antagonist, which has recently completed a phase IIb study ...
... ... in a new denture retention system procedure that can add 20% profit to a dental practice. ... (PRWEB) June 16, 2010 -- The ... new denture retention system procedure that can add 20% profit to a dental practice the ...
Cached Biology Technology:Free Web Cast On Fueling Ohio's New Job Growth 2Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis 2Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis 3Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis 4Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis 5Summit Dental Institute Offers A Hands-On One-Day Imtec MDI Mini Dental Implant Certification Course For Dentists 2Summit Dental Institute Offers A Hands-On One-Day Imtec MDI Mini Dental Implant Certification Course For Dentists 3Summit Dental Institute Offers A Hands-On One-Day Imtec MDI Mini Dental Implant Certification Course For Dentists 4
(Date:1/22/2015)... Inc. , a market leader of iris-based identity authentication solutions, ... the new role of Senior Vice President of Mobile and ... platforms and wearable solutions for EyeLock,s technologies. Gerber brings more ... industry to his role at EyeLock, with expertise in human ...
(Date:12/22/2014)... Dec. 22, 2014  The 2014 Holiday Season may be ... Market Intelligence reports that the long anticipated floodgates for ... intensifying demand for smart phones, tablets, and wearable mobile ... of 2.5 billion users with nearly 4.8 billion biometric ...
(Date:12/17/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ) ... S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis" ... http://photos.prnewswire.com/prnh/20130307/600769 Based on a totally ... for the first time a fingerprint sensor in its ...
Breaking Biology News(10 mins):EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
... in molecular targeting, translational cancer research and cancer ... 17,000 scientists from around the world gather at ... the 2008 Annual Meeting of the American Association ... the meeting will include late-breaking clinical trial findings ...
... plant withers unproductively or thrives in salty conditions may ... mechanism that controls salt tolerance has been found in ... collaborating with an international team. Complex-N-glycan, a ... previously thought to have no helpful function for plant ...
... A. Strobel, Professor of Molecular Biophysics and Biochemistry, ... Award. The award is given by American ... outstanding scientific contributions made by young researchers early ... award lecture, titled Three Views of RNA Catalysis: ...
Cached Biology News:AACR annual meeting showcases developments in understanding and targeting cancers 2AACR annual meeting showcases developments in understanding and targeting cancers 3Salt-tolerant gene found in simple plant nothing to sneeze at 2Yale University's Strobel recognized for work on RNA 2
... This special concentrated jetSI 10 nM is ... into mouse brain as described in: Z. ... C. Giovannangeli, J.-P. Behr, and B.-A. Demeneix. ... expression in the mouse brain at picomolar ...
... jetSI-ENDO-FluoF is a ... nm; emission at 520 nm), ... These reagents are used to ... investigate the intracellular delivery and ...
... R&D Systems Cell and Tissue Staining ... in a broad range of histological and ... with primary IgG antibodies manufactured by either ... detection is based on the formation of ...
... covers a wide range of hands-on techniques ... researchers in all areas of protein chemistry ... books preface illustrates just how valuable this ... The chapters introduce the theoretical background of ...
Biology Products: